サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：ランバート・イートン筋無力症候群の世界市場－成長、将来展望、競合分析（2022年～2030年）
市場調査レポート
商品コード
1149077

ランバート・イートン筋無力症候群の世界市場－成長、将来展望、競合分析（2022年～2030年）

Lambert-Eaton Myasthenic Syndrome Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日: | 発行: Acute Market Reports | ページ情報: 英文 118 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.58円
ランバート・イートン筋無力症候群の世界市場－成長、将来展望、競合分析（2022年～2030年）
出版日: 2022年08月23日
発行: Acute Market Reports
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のランバート・イートン筋無力症候群の市場規模は、2019年から2027年の予測期間中に6.7％のCAGRで成長すると予想されています。希少疾患治療のための臨床研究の大幅な増加、希少疾患の治療に対する財政支援を行う政府の積極的な取り組みは、ランバート・イートン筋無力症候群市場の成長を促進しています。

当レポートでは、世界のランバート・イートン筋無力症候群市場について調査分析し、ビジネス展望、市場力学、市場分析、企業プロファイルなど、体系的な情報を提供しています。

目次

第1章 序文

  • レポートの説明
    • レポートの目的
    • 対象者
    • 主な製品
  • 市場セグメンテーション
  • 調査手法
    • フェーズⅠ－2次調査
    • フェーズⅡ－1次調査
    • フェーズⅢ－専門家による審査
    • 仮定
    • 採用されたアプローチ

第2章 エグゼクティブサマリー

  • 市場スナップショット：世界のランバート・イートン筋無力症候群市場
  • 世界のランバート・イートン筋無力症候群市場（100万米ドル）（2021年）：治療別
  • 世界のランバート・イートン筋無力症候群市場（100万米ドル）：地域別
  • COVID-19の影響
  • 魅力的な投資提案（2021年）：地域別
  • 競合分析
    • 主要なランバート・イートン筋無力症候群市場ベンダーの市場ポジショニング
    • ランバート・イートン筋無力症候群の市場ベンダーが採用した戦略
    • 主要な業界戦略

第3章 ランバート・イートン筋無力症候群市場：ビジネス展望と市場力学

  • イントロダクション
  • 世界のランバート・イートン筋無力症候群の市場金額（100万米ドル）（2020年～2030年）
  • 市場力学
    • 市場促進要因
    • 市場抑制要因
    • 主な課題
    • 主な機会
  • 促進要因と抑制要因の影響分析
  • シーソー分析
  • ポーターのファイブフォースモデル
    • サプライヤーの力
    • バイヤーの力
    • 代替品の脅威
    • 新規参入業者の脅威
    • 競争企業間の敵対関係
  • PESTEL分析
    • 政治的
    • 経済的
    • 技術的
    • 法的
    • 社会的

第4章 ランバート・イートン筋無力症候群市場、米ドル（100万）（2020年～2030年）：治療別

  • 市場概要
  • 成長と収益分析：2021年と2030年の比較
  • 市場セグメンテーション
    • カリウムチャネル遮断薬（アミファンプリジン）
    • コリンエステラーゼ阻害剤（ピリドスチグミン）
    • 免疫療法
    • 静脈内免疫グロブリン
    • 血漿交換法

第5章 北米のランバート・イートン筋無力症候群市場、米ドル（100万）（2020年～2030年）

第6章 英国および欧州連合のランバート・イートン筋無力症候群市場、米ドル（100万）（2020年～2030年）

第7章 アジア太平洋のランバート・イートン筋無力症候群市場、米ドル（100万）（2020年～2030年）

第8章 ラテンアメリカのランバート・イートン筋無力症候群市場、米ドル（100万）（2020年～2030年）

第9章 中東およびアフリカのランバート・イートン筋無力症候群市場、米ドル（100万）（2020年～2030年）

第10章 企業プロファイル

  • Allergan, Plc.
  • Biomarin Pharmaceutical, Inc.
  • Catalyst Pharmaceuticals, Inc.
  • F. Hoffman-La Roche Ltd.
  • GlaxoSmithkline, Plc.
  • Jacobus Pharmaceutical Company, Inc.
  • Kawasumi Laboratories, Inc.
  • Merck & Co., Inc.
  • Mitsubishi Pharma Corporation
  • Novartis AG
図表

List of Tables

  • TABLE 1 Global Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
  • TABLE 2 North America Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
  • TABLE 3 UK and European Union Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
  • TABLE 4 Asia Pacific Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
  • TABLE 5 Latin America Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)
  • TABLE 6 Middle East and Africa Lambert-Eaton Myasthenic Syndrome Market By Treatment, 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Lambert-Eaton Myasthenic Syndrome Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Lambert-Eaton Myasthenic Syndrome Market: Quality Assurance
  • FIG. 5 Global Lambert-Eaton Myasthenic Syndrome Market, By Treatment, 2021
  • FIG. 6 Global Lambert-Eaton Myasthenic Syndrome Market, By Geography, 2021
  • FIG. 7 Global Lambert-Eaton Myasthenic Syndrome Market, By Treatment, 2021 Vs 2030, %
  • FIG. 8 U.S. Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 9 Canada Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 10 Rest of North America Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 11 UK Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 12 Germany Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 13 Spain Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 14 Italy Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 15 France Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 16 Rest of Europe Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 17 China Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 18 Japan Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 19 India Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 20 Australia Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 21 South Korea Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 22 Rest of Asia Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 23 Brazil Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 24 Mexico Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 25 Rest of Latin America Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 26 GCC Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 27 Africa Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
  • FIG. 28 Rest of Middle East and Africa Lambert-Eaton Myasthenic Syndrome Market (US$ Million), 2020 - 2030
目次
Product Code: 138734-08-22

Industry Outlook

The Lambert-Eaton Myasthenic Syndrome (LEMS) market is keen to represent linear growth at a compounded annual growth rate (CAGR) of 6.7% during the forecast period from 2019 to 2027. LEMS is a rare autoimmune disorder which is manifested by the clinical triad which comprises of reduced tendon reflexes, autonomic symptoms and proximal muscle weakness. Most of the patients suffering with LEMS go undiagnosed at an early age due to its overlapping symptoms similar to small cell lung cancer (SCLC).

Recent FDA approval of amifampridine for treating LEMS in children and fast track & orphan drug designation to incentivize its growth during the forecast period

Currently there is no permanent cure for the treatment of LEMS disease in children, the medicine prescribed by physicians worldwide are to attenuate the clinical manifestations related to LEMS disease. Depending on the identification of the symptoms occurring in the adult population the drugs prescribed for its treatment are potassium channel blockers, cholinesterase inhibitor, immune therapy, intravenous immunoglobulin, Plasmapheresis etc. USFDA has recently approved amifampridine for the treatment of LEMS in children from 6 to 17 years of age. It has received orphan drug and fast track designation status which will proactively incentivize the drug development for curing rare diseases.

Significant rise in clinical research to cure orphan diseases and domicile of major players together drive the market growth in North America region

North America is currently dominating the regional segment for Lambert-Eaton Myasthenic syndrome (LEMS) market holding 39% share. The major factors responsible for its positive growth profile are significant rise in clinical research activities to cure orphan diseases. According to the Center for Disease Control and Prevention (CDC), research findings approximately 3% of the patients suffering with small cell lung cancer (SCLC) are suffering with Lambert-Eaton Myasthenic syndrome (LEMS). The prevalence rate of SCLC in the United States is 5 cases per million population. Domicile of major players such as Biomarin Pharmaceutical, Inc., Catalyst, Pharmaceuticals, Inc., Merck & Co., Inc. etc. propel the market growth in North America region. Europe holds the second position representing a market share of 34.5% owing to the high incidence rate of LEMS in the European community. As per the research citing of European LEMS Registry the incidence rate is 0.48 to 0.75 per million people, the low prevalence rate I comparison to the incidence rate is due to the poor survival of LEMS patient with paraneoplastic type of disease. Asia Pacific is currently holding 14% market share primarily due to large patient population suffering with SCLC and proactive government initiatives in providing financial aid for the treatment of rare diseases.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Lambert-Eaton Myasthenic Syndrome market are as follows:

  • Research and development budgets of manufacturers and government spending
  • Revenues of key companies in the market segment
  • Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Lambert-Eaton Myasthenic Syndrome market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Treatment

  • Potassium Channel Blockers (Amifampridine)
  • Cholinesterase Inhibitor (Pyridostigmine)
  • Immune Therapy
  • Intravenous Immunoglobulin
  • Plasmapheresis

Region Segment (2020-2030; US$ Million)

  • North America
    • U.S.
    • Canada
    • Rest of North America
  • UK and European Union
    • UK
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

  • Pre COVID-19 situation
  • Post COVID-19 situation

Key questions answered in this report:

  • What are the key micro and macro environmental factors that are impacting the growth of Lambert-Eaton Myasthenic Syndrome market?
  • What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
  • Estimated forecast and market projections up to 2030.
  • Which segment accounts for the fastest CAGR during the forecast period?
  • Which market segment holds a larger market share and why?
  • Are low and middle-income economies investing in the Lambert-Eaton Myasthenic Syndrome market?
  • Which is the largest regional market for Lambert-Eaton Myasthenic Syndrome market?
  • What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
  • Which are the key trends driving Lambert-Eaton Myasthenic Syndrome market growth?
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Lambert-Eaton Myasthenic Syndrome market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Lambert-Eaton Myasthenic Syndrome Market
  • 2.2. Global Lambert-Eaton Myasthenic Syndrome Market, By Treatment, 2021 (US$ Million)
  • 2.3. Global Lambert-Eaton Myasthenic Syndrome Market, By Geography, 2021 (US$ Million)
  • 2.4. Impact of Covid 19
  • 2.5. Attractive Investment Proposition by Geography, 2021
  • 2.6. Competitive Analysis
    • 2.6.1. Market Positioning of Key Lambert-Eaton Myasthenic Syndrome Market Vendors
    • 2.6.2. Strategies Adopted by Lambert-Eaton Myasthenic Syndrome Market Vendors
    • 2.6.3. Key Industry Strategies

3. Lambert-Eaton Myasthenic Syndrome Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Lambert-Eaton Myasthenic Syndrome Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation
    • 4.3.1. Potassium Channel Blockers (Amifampridine)
    • 4.3.2. Cholinesterase Inhibitor (Pyridostigmine)
    • 4.3.3. Immune Therapy
    • 4.3.4. Intravenous Immunoglobulin
    • 4.3.5. Plasmapheresis

5. North America Lambert-Eaton Myasthenic Syndrome Market, 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
  • 5.3.Lambert-Eaton Myasthenic Syndrome Market: By Region, 2020-2030, USD (Million)
    • 5.3.1.North America
      • 5.3.1.1. U.S.
      • 5.3.1.2. Canada
      • 5.3.1.3. Rest of North America

6. UK and European Union Lambert-Eaton Myasthenic Syndrome Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
  • 6.3.Lambert-Eaton Myasthenic Syndrome Market: By Region, 2020-2030, USD (Million)
    • 6.3.1.UK and European Union
      • 6.3.1.1. UK
      • 6.3.1.2. Germany
      • 6.3.1.3. Spain
      • 6.3.1.4. Italy
      • 6.3.1.5. France
      • 6.3.1.6. Rest of Europe

7. Asia Pacific Lambert-Eaton Myasthenic Syndrome Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
  • 7.3.Lambert-Eaton Myasthenic Syndrome Market: By Region, 2020-2030, USD (Million)
    • 7.3.1.Asia Pacific
      • 7.3.1.1. China
      • 7.3.1.2. Japan
      • 7.3.1.3. India
      • 7.3.1.4. Australia
      • 7.3.1.5. South Korea
      • 7.3.1.6. Rest of Asia Pacific

8. Latin America Lambert-Eaton Myasthenic Syndrome Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
  • 8.3.Lambert-Eaton Myasthenic Syndrome Market: By Region, 2020-2030, USD (Million)
    • 8.3.1.Latin America
      • 8.3.1.1. Brazil
      • 8.3.1.2. Mexico
      • 8.3.1.3. Rest of Latin America

9. Middle East and Africa Lambert-Eaton Myasthenic Syndrome Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Lambert-Eaton Myasthenic Syndrome Market: By Treatment, 2020-2030, USD (Million)
  • 9.3.Lambert-Eaton Myasthenic Syndrome Market: By Region, 2020-2030, USD (Million)
    • 9.3.1.Middle East and Africa
      • 9.3.1.1. GCC
      • 9.3.1.2. Africa
      • 9.3.1.3. Rest of Middle East and Africa

10. Company Profile

  • 10.1. Allergan, Plc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Initiatives
  • 10.2. Biomarin Pharmaceutical, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Initiatives
  • 10.3. Catalyst Pharmaceuticals, Inc.
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Product Portfolio
    • 10.3.4. Strategic Initiatives
  • 10.4. F. Hoffman-La Roche Ltd.
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Initiatives
  • 10.5. GlaxoSmithkline, Plc.
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Initiatives
  • 10.6. Jacobus Pharmaceutical Company, Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Product Portfolio
    • 10.6.4. Strategic Initiatives
  • 10.7. Kawasumi Laboratories, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Product Portfolio
    • 10.7.4. Strategic Initiatives
  • 10.8. Merck & Co., Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Product Portfolio
    • 10.8.4. Strategic Initiatives
  • 10.9. Mitsubishi Pharma Corporation
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Product Portfolio
    • 10.9.4. Strategic Initiatives
  • 10.10. Novartis AG
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Initiatives